To further advance the "Industry-Strong City" strategy, and relying on Nanjing’s "4+N" industrial fund cluster collaboration mechanism featuring government guidance, market operation, and multi-party coordination, Nanjing Innovation Investment Group, under the guidance of the Nanjing Municipal Development and Reform Commission (NDRC) and the Nanjing Municipal Biomedical Industry Tackling Office, focused on the core goal of promoting industrial upgrading through scientific and technological innovation and striving to maintain leadership in high-quality development. On the afternoon of August 20, it successfully held the event "2025 Nanjing Key Industrial Project Roadshow & Industry-Finance Cooperation Matching Meeting – Biomedical Special Session".

The event brought together guests from relevant investment institutions, banks, securities firms, and enterprise representatives. All parties conducted in-depth discussions and matchmaking focusing on the innovative applications and investment prospects in the biomedical field, injecting strong capital impetus into the accelerated development of the industry.

Wu Shiyong, Head of the Financial Services Group of Nanjing Municipal Biomedical Industry Tackling Office and Deputy Director of the Second Coordination & Service Division of Nanjing Municipal Financial Work Office, stated that since its establishment, the Tackling Office has focused on the pain points and difficulties in the development of the biomedical industry. It has strived to solve problems such as enterprise financing and promote the integration of industrial resources through measures including establishing a list of industrial chain enterprises, building a government-bank-enterprise communication platform, and advancing the precise implementation of policies.

In the next step, the Tackling Office will continue to optimize its service mechanism. On the one hand, it will deepen cooperation with various financial institutions and introduce more professional investment forces; on the other hand, it will provide customized service plans based on the financing needs of enterprises at different development stages to support enterprise growth and inject financial momentum into the high-quality development of the biomedical industry.

Four highly promising enterprises took the stage in sequence to showcase their cutting-edge technologies and project achievements. They are Nanjing Jisi Huiyuan Biotechnology Co., Ltd., Jiangsu Weikai'er Pharmaceutical Technology Co., Ltd., Nanjing Sainuo Biopharmaceutical Co., Ltd., and Jiangsu Meide Pharmaceutical Technology Co., Ltd. In their roadshow presentations, each enterprise not only elaborated on their technological innovation highlights and core competitiveness in detail but also clearly demonstrated their market positioning, revenue forecasts, and financing needs. After the roadshow, representatives from investment institutions conducted in-depth discussions with the enterprises on key issues such as technical barriers, large-scale application, and policy adaptability. The on-site interaction was frequent, and the intention for cooperation was strong. In addition, a number of enterprises in Nanjing with financing needs also attended the event to participate in exchanges.

The successful holding of this biomedical-themed roadshow and matching meeting is not only a concrete practice of Nanjing’s promotion of the "4+N" industrial fund cluster construction but also a vivid reflection of the in-depth integration of industry and capital. Through government departments building platforms and guiding directions, investment institutions providing precise empowerment and injecting capital, and enterprises deepening technology and exploring markets, this multi-party collaboration mechanism will jointly promote Nanjing’s biomedical industry to a new level and create a strong engine for the high-quality development of the city’s economy.

This event was guided by Nanjing Municipal Development and Reform Commission, Nanjing Municipal Bureau of Science and Technology, Nanjing Municipal Financial Work Office, CPC Nanjing Biomedical Industry Chain Committee, and Nanjing Biomedical Industry Tackling and Promotion Office; hosted by Nanjing Innovation Investment Group; co-organized by Nanjing Venture Capital Alliance and Maker Commune; and co-sponsored by Yida Capital. Venture capital institutions including Nanjing Venture Capital Group, Yida Capital, Jiuzhou Venture Capital, Shenzhen Venture Capital, CICC, Yingchengxin Capital, and Dynamic Balance, as well as financial institutions such as Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of China, Bank of Jiangsu, Bank of Nanjing, Bank of Ningbo, Nanjing Securities, TF Securities, Nanjing Zijin Financial Guarantee, and Jiangsu Financial Leasing, participated in the event. In addition, Nanjing Venture Capital Alliance will provide follow-up and companionship services for the projects to promote the "precision matching" between capital and industry.